News & Updates
Filter by Specialty:
Show Multimedia Only
Is pembrolizumab-lenvatinib effective in recurrent endometrial cancer?
05 Sep 2023
Combination treatment with pembrolizumab and lenvatinib appears to be a better option for patients with recurrent endometrial cancer (REC) or advanced endometrial cancer (AEC) with a platinum-free interval (PFI) of <6 months, suggests a recent study.
Is pembrolizumab-lenvatinib effective in recurrent endometrial cancer?
05 Sep 2023
Worsening kidney function ups ASCVD risk
05 Sep 2023
byStephen Padilla
Individuals with worsening kidney function are at greater risk of future atherosclerotic cardiovascular diseases (ASCVD), and such risk is more evident among women, according to a study.
Worsening kidney function ups ASCVD risk
05 Sep 2023
Parkinson’s disease: More hours of good on-time with extended- vs immediate-release carbidopa-levodopa
05 Sep 2023
byNatalia Reoutova
IPX203, a new oral extended-release (ER) carbidopa-levodopa (CD-LD) combination, provides more hours of good on-time per day than immediate-release (IR) CD-LD, according to results of a phase III clinical trial in patients with Parkinson’s disease (PD).